http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 13 Jul 2026 08:44:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Voyager+Therapeutics%2C+++++For%3A+Jul+13/26760398.html si-local-file:///var/storage/secattach/20260713/26760398.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Voyager+Therapeutics%2C+++++For%3A+Jul+13/26760398.html Mon, 13 Jul 2026 08:44:00 -0400 O.17919569 VYGR http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Voyager+Therapeutics%2C+++++For%3A+Jul+13/26760398.html si-local-file:///var/storage/secattach/20260713/26760398.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Voyager+Therapeutics%2C+++++For%3A+Jul+13/26760398.html Mon, 13 Jul 2026 08:44:00 -0400 O.17919569 VYGR http://www.streetinsider.com/Corporate+News/Voyager+tau+gene+therapy+shows+tolerability+in+6-month+NHP+study/26760158.html <p>Voyager Therapeutics, Inc. (Nasdaq: VYGR) presented six-month toxicology data for its investigational gene therapy VY1706, targeting tau protein in Alzheimer's disease, at the Alzheimer's Association International Conference in London on July 13, 2026.</p><p>The data, drawn from a good laboratory practice study in non-human primates, showed that a single intravenous dose of VY1706 was well tolerated, with no adverse clinical pathology or histopathological findings in the central nervous system, dorsal root ganglia, or peripheral organs, including the liver, at the highest dose tested of 5E13 vg/kg.</p><p>VY1706 achieved up to 75% reduction in MAPT mRNA and tau protein in Alzheimer's disease-relevant brain http://www.streetinsider.com/Corporate+News/Voyager+tau+gene+therapy+shows+tolerability+in+6-month+NHP+study/26760158.html Mon, 13 Jul 2026 08:04:25 -0400 VYGR http://www.streetinsider.com/FDA/Voyager+tau+gene+therapy+shows+tolerability+in+6-month+NHP+study/26760158.html <p>Voyager Therapeutics, Inc. (Nasdaq: VYGR) presented six-month toxicology data for its investigational gene therapy VY1706, targeting tau protein in Alzheimer's disease, at the Alzheimer's Association International Conference in London on July 13, 2026.</p><p>The data, drawn from a good laboratory practice study in non-human primates, showed that a single intravenous dose of VY1706 was well tolerated, with no adverse clinical pathology or histopathological findings in the central nervous system, dorsal root ganglia, or peripheral organs, including the liver, at the highest dose tested of 5E13 vg/kg.</p><p>VY1706 achieved up to 75% reduction in MAPT mRNA and tau protein in Alzheimer's disease-relevant brain http://www.streetinsider.com/FDA/Voyager+tau+gene+therapy+shows+tolerability+in+6-month+NHP+study/26760158.html Mon, 13 Jul 2026 08:04:25 -0400 VYGR http://www.streetinsider.com/Press+Releases/Voyager+Demonstrates+Single+IV+Dose+of+VY1706+Well+Tolerated%2C+Reduced+Tau+in+6-Month+GLP+Toxicology+Study%3B+Initiation+of+Clinical+Trial+in+Alzheimer%E2%80%99s+Disease+Expected+H2+2026/26760102.html <p align="center"><em>- Data presented as Developing Topics poster at AAIC 2026 -</em></p> <p>LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today presented six-month good laboratory practice (GLP) toxicology data for VY1706, the Company’s investigational gene therapy targeting intracellular and extracellular tau for Alzheimer’s disease (AD), in a Developing Topics (late-breaking) poster presentation at the Alzheimer&apos;s Association International Conference (AAIC) taking place in London, July 12-15, 2026. Data presented showed that VY1706 was well tolerated and resulted in sustained tau protein reduction http://www.streetinsider.com/Press+Releases/Voyager+Demonstrates+Single+IV+Dose+of+VY1706+Well+Tolerated%2C+Reduced+Tau+in+6-Month+GLP+Toxicology+Study%3B+Initiation+of+Clinical+Trial+in+Alzheimer%E2%80%99s+Disease+Expected+H2+2026/26760102.html Mon, 13 Jul 2026 08:01:00 -0400 A.06822034 O.17919569 O.20026344 VYGR http://www.streetinsider.com/Press+Releases/Voyager+Demonstrates+Single+IV+Dose+of+VY1706+Well+Tolerated%2C+Reduced+Tau+in+6-Month+GLP+Toxicology+Study%3B+Initiation+of+Clinical+Trial+in+Alzheimer%E2%80%99s+Disease+Expected+H2+2026/26760102.html <p align="center"><em>- Data presented as Developing Topics poster at AAIC 2026 -</em></p> <p>LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today presented six-month good laboratory practice (GLP) toxicology data for VY1706, the Company’s investigational gene therapy targeting intracellular and extracellular tau for Alzheimer’s disease (AD), in a Developing Topics (late-breaking) poster presentation at the Alzheimer&apos;s Association International Conference (AAIC) taking place in London, July 12-15, 2026. Data presented showed that VY1706 was well tolerated and resulted in sustained tau protein reduction http://www.streetinsider.com/Press+Releases/Voyager+Demonstrates+Single+IV+Dose+of+VY1706+Well+Tolerated%2C+Reduced+Tau+in+6-Month+GLP+Toxicology+Study%3B+Initiation+of+Clinical+Trial+in+Alzheimer%E2%80%99s+Disease+Expected+H2+2026/26760102.html Mon, 13 Jul 2026 08:01:00 -0400 A.06822034 O.17919569 O.20026344 VYGR http://www.streetinsider.com/Press+Releases/Voyager+Demonstrates+Single+IV+Dose+of+VY1706+Well+Tolerated%2C+Reduced+Tau+in+6-Month+GLP+Toxicology+Study%3B+Initiation+of+Clinical+Trial+in+Alzheimer%E2%80%99s+Disease+Expected+H2+2026/26760102.html <p align="center"><em>- Data presented as Developing Topics poster at AAIC 2026 -</em></p> <p>LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today presented six-month good laboratory practice (GLP) toxicology data for VY1706, the Company’s investigational gene therapy targeting intracellular and extracellular tau for Alzheimer’s disease (AD), in a Developing Topics (late-breaking) poster presentation at the Alzheimer&apos;s Association International Conference (AAIC) taking place in London, July 12-15, 2026. Data presented showed that VY1706 was well tolerated and resulted in sustained tau protein reduction http://www.streetinsider.com/Press+Releases/Voyager+Demonstrates+Single+IV+Dose+of+VY1706+Well+Tolerated%2C+Reduced+Tau+in+6-Month+GLP+Toxicology+Study%3B+Initiation+of+Clinical+Trial+in+Alzheimer%E2%80%99s+Disease+Expected+H2+2026/26760102.html Mon, 13 Jul 2026 08:01:00 -0400 A.06822034 O.17919569 O.20026344 VYGR http://www.streetinsider.com/Press+Releases/Voyager+Demonstrates+Single+IV+Dose+of+VY1706+Well+Tolerated%2C+Reduced+Tau+in+6-Month+GLP+Toxicology+Study%3B+Initiation+of+Clinical+Trial+in+Alzheimer%E2%80%99s+Disease+Expected+H2+2026/26760102.html <p align="center"><em>- Data presented as Developing Topics poster at AAIC 2026 -</em></p> <p>LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today presented six-month good laboratory practice (GLP) toxicology data for VY1706, the Company’s investigational gene therapy targeting intracellular and extracellular tau for Alzheimer’s disease (AD), in a Developing Topics (late-breaking) poster presentation at the Alzheimer&apos;s Association International Conference (AAIC) taking place in London, July 12-15, 2026. Data presented showed that VY1706 was well tolerated and resulted in sustained tau protein reduction http://www.streetinsider.com/Press+Releases/Voyager+Demonstrates+Single+IV+Dose+of+VY1706+Well+Tolerated%2C+Reduced+Tau+in+6-Month+GLP+Toxicology+Study%3B+Initiation+of+Clinical+Trial+in+Alzheimer%E2%80%99s+Disease+Expected+H2+2026/26760102.html Mon, 13 Jul 2026 08:01:00 -0400 A.06822034 O.17919569 O.20026344 VYGR http://www.streetinsider.com/Globe+Newswire/Voyager+Demonstrates+Single+IV+Dose+of+VY1706+Well+Tolerated%2C+Reduced+Tau+in+6-Month+GLP+Toxicology+Study%3B+Initiation+of+Clinical+Trial+in+Alzheimer%E2%80%99s+Disease+Expected+H2+2026/26760102.html <p align="center"><em>- Data presented as Developing Topics poster at AAIC 2026 -</em></p> <p>LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today presented six-month good laboratory practice (GLP) toxicology data for VY1706, the Company’s investigational gene therapy targeting intracellular and extracellular tau for Alzheimer’s disease (AD), in a Developing Topics (late-breaking) poster presentation at the Alzheimer&apos;s Association International Conference (AAIC) taking place in London, July 12-15, 2026. Data presented showed that VY1706 was well tolerated and resulted in sustained tau protein reduction http://www.streetinsider.com/Globe+Newswire/Voyager+Demonstrates+Single+IV+Dose+of+VY1706+Well+Tolerated%2C+Reduced+Tau+in+6-Month+GLP+Toxicology+Study%3B+Initiation+of+Clinical+Trial+in+Alzheimer%E2%80%99s+Disease+Expected+H2+2026/26760102.html Mon, 13 Jul 2026 08:01:00 -0400 A.06822034 O.17919569 O.20026344 VYGR http://www.streetinsider.com/Globe+Newswire/Voyager+Demonstrates+Single+IV+Dose+of+VY1706+Well+Tolerated%2C+Reduced+Tau+in+6-Month+GLP+Toxicology+Study%3B+Initiation+of+Clinical+Trial+in+Alzheimer%E2%80%99s+Disease+Expected+H2+2026/26760102.html <p align="center"><em>- Data presented as Developing Topics poster at AAIC 2026 -</em></p> <p>LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today presented six-month good laboratory practice (GLP) toxicology data for VY1706, the Company’s investigational gene therapy targeting intracellular and extracellular tau for Alzheimer’s disease (AD), in a Developing Topics (late-breaking) poster presentation at the Alzheimer&apos;s Association International Conference (AAIC) taking place in London, July 12-15, 2026. Data presented showed that VY1706 was well tolerated and resulted in sustained tau protein reduction http://www.streetinsider.com/Globe+Newswire/Voyager+Demonstrates+Single+IV+Dose+of+VY1706+Well+Tolerated%2C+Reduced+Tau+in+6-Month+GLP+Toxicology+Study%3B+Initiation+of+Clinical+Trial+in+Alzheimer%E2%80%99s+Disease+Expected+H2+2026/26760102.html Mon, 13 Jul 2026 08:01:00 -0400 A.06822034 O.17919569 O.20026344 VYGR http://www.streetinsider.com/Globe+Newswire/Voyager+Demonstrates+Single+IV+Dose+of+VY1706+Well+Tolerated%2C+Reduced+Tau+in+6-Month+GLP+Toxicology+Study%3B+Initiation+of+Clinical+Trial+in+Alzheimer%E2%80%99s+Disease+Expected+H2+2026/26760102.html <p align="center"><em>- Data presented as Developing Topics poster at AAIC 2026 -</em></p> <p>LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today presented six-month good laboratory practice (GLP) toxicology data for VY1706, the Company’s investigational gene therapy targeting intracellular and extracellular tau for Alzheimer’s disease (AD), in a Developing Topics (late-breaking) poster presentation at the Alzheimer&apos;s Association International Conference (AAIC) taking place in London, July 12-15, 2026. Data presented showed that VY1706 was well tolerated and resulted in sustained tau protein reduction http://www.streetinsider.com/Globe+Newswire/Voyager+Demonstrates+Single+IV+Dose+of+VY1706+Well+Tolerated%2C+Reduced+Tau+in+6-Month+GLP+Toxicology+Study%3B+Initiation+of+Clinical+Trial+in+Alzheimer%E2%80%99s+Disease+Expected+H2+2026/26760102.html Mon, 13 Jul 2026 08:01:00 -0400 A.06822034 O.17919569 O.20026344 VYGR http://www.streetinsider.com/Globe+Newswire/Voyager+Demonstrates+Single+IV+Dose+of+VY1706+Well+Tolerated%2C+Reduced+Tau+in+6-Month+GLP+Toxicology+Study%3B+Initiation+of+Clinical+Trial+in+Alzheimer%E2%80%99s+Disease+Expected+H2+2026/26760102.html <p align="center"><em>- Data presented as Developing Topics poster at AAIC 2026 -</em></p> <p>LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today presented six-month good laboratory practice (GLP) toxicology data for VY1706, the Company’s investigational gene therapy targeting intracellular and extracellular tau for Alzheimer’s disease (AD), in a Developing Topics (late-breaking) poster presentation at the Alzheimer&apos;s Association International Conference (AAIC) taking place in London, July 12-15, 2026. Data presented showed that VY1706 was well tolerated and resulted in sustained tau protein reduction http://www.streetinsider.com/Globe+Newswire/Voyager+Demonstrates+Single+IV+Dose+of+VY1706+Well+Tolerated%2C+Reduced+Tau+in+6-Month+GLP+Toxicology+Study%3B+Initiation+of+Clinical+Trial+in+Alzheimer%E2%80%99s+Disease+Expected+H2+2026/26760102.html Mon, 13 Jul 2026 08:01:00 -0400 A.06822034 O.17919569 O.20026344 VYGR http://www.streetinsider.com/Corporate+News/Voyager+to+present+Alzheimer%27s+gene+therapy+data+at+AAIC+2026/26702433.html <p>Voyager Therapeutics (Nasdaq: VYGR) will present preclinical data on its investigational Alzheimer's disease gene therapy VY1706 at the Alzheimer's Association International Conference (AAIC) in London, running July 12–15, 2026.</p><p>The presentation, classified as a Developing Topics late-breaking poster, is scheduled for Monday, July 13, 2026, from 7:30 a.m. to 4:15 p.m. GMT. It will cover results from an IND-enabling good laboratory practice toxicology study conducted in non-human primates.</p><p>VY1706 is a gene therapy designed to reduce tau protein levels in the brain via a vectorized siRNA targeting MAPT mRNA. The therapy is delivered using Voyager's TRACER AAV capsid platform through a single http://www.streetinsider.com/Corporate+News/Voyager+to+present+Alzheimer%27s+gene+therapy+data+at+AAIC+2026/26702433.html Mon, 29 Jun 2026 08:03:33 -0400 VYGR http://www.streetinsider.com/Press+Releases/Voyager%E2%80%99s+Tau-Targeted+Gene+Therapy+VY1706+for+Alzheimer%E2%80%99s+Disease+to+Be+Featured+in+Developing+Topics+Poster+Presentation+at+AAIC+2026/26702376.html <p>LEXINGTON, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced a Developing Topics (late-breaking) poster presentation at the upcoming Alzheimer&apos;s Association International Conference (AAIC) taking place in London, July 12-15, 2026. The Developing Topics poster presentation will feature VY1706, Voyager’s investigational gene therapy targeting intracellular and extracellular tau for Alzheimer’s disease (AD). Earlier this month, Voyager received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) clearance for VY1706, enabling initiation of a clinical trial in adults with early AD, with http://www.streetinsider.com/Press+Releases/Voyager%E2%80%99s+Tau-Targeted+Gene+Therapy+VY1706+for+Alzheimer%E2%80%99s+Disease+to+Be+Featured+in+Developing+Topics+Poster+Presentation+at+AAIC+2026/26702376.html Mon, 29 Jun 2026 08:01:00 -0400 A.06822034 O.17919569 O.20026344 VYGR http://www.streetinsider.com/Press+Releases/Voyager%E2%80%99s+Tau-Targeted+Gene+Therapy+VY1706+for+Alzheimer%E2%80%99s+Disease+to+Be+Featured+in+Developing+Topics+Poster+Presentation+at+AAIC+2026/26702376.html <p>LEXINGTON, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced a Developing Topics (late-breaking) poster presentation at the upcoming Alzheimer&apos;s Association International Conference (AAIC) taking place in London, July 12-15, 2026. The Developing Topics poster presentation will feature VY1706, Voyager’s investigational gene therapy targeting intracellular and extracellular tau for Alzheimer’s disease (AD). Earlier this month, Voyager received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) clearance for VY1706, enabling initiation of a clinical trial in adults with early AD, with http://www.streetinsider.com/Press+Releases/Voyager%E2%80%99s+Tau-Targeted+Gene+Therapy+VY1706+for+Alzheimer%E2%80%99s+Disease+to+Be+Featured+in+Developing+Topics+Poster+Presentation+at+AAIC+2026/26702376.html Mon, 29 Jun 2026 08:01:00 -0400 A.06822034 O.17919569 O.20026344 VYGR http://www.streetinsider.com/Press+Releases/Voyager%E2%80%99s+Tau-Targeted+Gene+Therapy+VY1706+for+Alzheimer%E2%80%99s+Disease+to+Be+Featured+in+Developing+Topics+Poster+Presentation+at+AAIC+2026/26702376.html <p>LEXINGTON, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced a Developing Topics (late-breaking) poster presentation at the upcoming Alzheimer&apos;s Association International Conference (AAIC) taking place in London, July 12-15, 2026. The Developing Topics poster presentation will feature VY1706, Voyager’s investigational gene therapy targeting intracellular and extracellular tau for Alzheimer’s disease (AD). Earlier this month, Voyager received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) clearance for VY1706, enabling initiation of a clinical trial in adults with early AD, with http://www.streetinsider.com/Press+Releases/Voyager%E2%80%99s+Tau-Targeted+Gene+Therapy+VY1706+for+Alzheimer%E2%80%99s+Disease+to+Be+Featured+in+Developing+Topics+Poster+Presentation+at+AAIC+2026/26702376.html Mon, 29 Jun 2026 08:01:00 -0400 A.06822034 O.17919569 O.20026344 VYGR http://www.streetinsider.com/Press+Releases/Voyager%E2%80%99s+Tau-Targeted+Gene+Therapy+VY1706+for+Alzheimer%E2%80%99s+Disease+to+Be+Featured+in+Developing+Topics+Poster+Presentation+at+AAIC+2026/26702376.html <p>LEXINGTON, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced a Developing Topics (late-breaking) poster presentation at the upcoming Alzheimer&apos;s Association International Conference (AAIC) taking place in London, July 12-15, 2026. The Developing Topics poster presentation will feature VY1706, Voyager’s investigational gene therapy targeting intracellular and extracellular tau for Alzheimer’s disease (AD). Earlier this month, Voyager received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) clearance for VY1706, enabling initiation of a clinical trial in adults with early AD, with http://www.streetinsider.com/Press+Releases/Voyager%E2%80%99s+Tau-Targeted+Gene+Therapy+VY1706+for+Alzheimer%E2%80%99s+Disease+to+Be+Featured+in+Developing+Topics+Poster+Presentation+at+AAIC+2026/26702376.html Mon, 29 Jun 2026 08:01:00 -0400 A.06822034 O.17919569 O.20026344 VYGR http://www.streetinsider.com/Globe+Newswire/Voyager%E2%80%99s+Tau-Targeted+Gene+Therapy+VY1706+for+Alzheimer%E2%80%99s+Disease+to+Be+Featured+in+Developing+Topics+Poster+Presentation+at+AAIC+2026/26702376.html <p>LEXINGTON, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced a Developing Topics (late-breaking) poster presentation at the upcoming Alzheimer&apos;s Association International Conference (AAIC) taking place in London, July 12-15, 2026. The Developing Topics poster presentation will feature VY1706, Voyager’s investigational gene therapy targeting intracellular and extracellular tau for Alzheimer’s disease (AD). Earlier this month, Voyager received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) clearance for VY1706, enabling initiation of a clinical trial in adults with early AD, with http://www.streetinsider.com/Globe+Newswire/Voyager%E2%80%99s+Tau-Targeted+Gene+Therapy+VY1706+for+Alzheimer%E2%80%99s+Disease+to+Be+Featured+in+Developing+Topics+Poster+Presentation+at+AAIC+2026/26702376.html Mon, 29 Jun 2026 08:01:00 -0400 A.06822034 O.17919569 O.20026344 VYGR http://www.streetinsider.com/Globe+Newswire/Voyager%E2%80%99s+Tau-Targeted+Gene+Therapy+VY1706+for+Alzheimer%E2%80%99s+Disease+to+Be+Featured+in+Developing+Topics+Poster+Presentation+at+AAIC+2026/26702376.html <p>LEXINGTON, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced a Developing Topics (late-breaking) poster presentation at the upcoming Alzheimer&apos;s Association International Conference (AAIC) taking place in London, July 12-15, 2026. The Developing Topics poster presentation will feature VY1706, Voyager’s investigational gene therapy targeting intracellular and extracellular tau for Alzheimer’s disease (AD). Earlier this month, Voyager received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) clearance for VY1706, enabling initiation of a clinical trial in adults with early AD, with http://www.streetinsider.com/Globe+Newswire/Voyager%E2%80%99s+Tau-Targeted+Gene+Therapy+VY1706+for+Alzheimer%E2%80%99s+Disease+to+Be+Featured+in+Developing+Topics+Poster+Presentation+at+AAIC+2026/26702376.html Mon, 29 Jun 2026 08:01:00 -0400 A.06822034 O.17919569 O.20026344 VYGR http://www.streetinsider.com/Globe+Newswire/Voyager%E2%80%99s+Tau-Targeted+Gene+Therapy+VY1706+for+Alzheimer%E2%80%99s+Disease+to+Be+Featured+in+Developing+Topics+Poster+Presentation+at+AAIC+2026/26702376.html <p>LEXINGTON, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced a Developing Topics (late-breaking) poster presentation at the upcoming Alzheimer&apos;s Association International Conference (AAIC) taking place in London, July 12-15, 2026. The Developing Topics poster presentation will feature VY1706, Voyager’s investigational gene therapy targeting intracellular and extracellular tau for Alzheimer’s disease (AD). Earlier this month, Voyager received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) clearance for VY1706, enabling initiation of a clinical trial in adults with early AD, with http://www.streetinsider.com/Globe+Newswire/Voyager%E2%80%99s+Tau-Targeted+Gene+Therapy+VY1706+for+Alzheimer%E2%80%99s+Disease+to+Be+Featured+in+Developing+Topics+Poster+Presentation+at+AAIC+2026/26702376.html Mon, 29 Jun 2026 08:01:00 -0400 A.06822034 O.17919569 O.20026344 VYGR http://www.streetinsider.com/Globe+Newswire/Voyager%E2%80%99s+Tau-Targeted+Gene+Therapy+VY1706+for+Alzheimer%E2%80%99s+Disease+to+Be+Featured+in+Developing+Topics+Poster+Presentation+at+AAIC+2026/26702376.html <p>LEXINGTON, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced a Developing Topics (late-breaking) poster presentation at the upcoming Alzheimer&apos;s Association International Conference (AAIC) taking place in London, July 12-15, 2026. The Developing Topics poster presentation will feature VY1706, Voyager’s investigational gene therapy targeting intracellular and extracellular tau for Alzheimer’s disease (AD). Earlier this month, Voyager received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) clearance for VY1706, enabling initiation of a clinical trial in adults with early AD, with http://www.streetinsider.com/Globe+Newswire/Voyager%E2%80%99s+Tau-Targeted+Gene+Therapy+VY1706+for+Alzheimer%E2%80%99s+Disease+to+Be+Featured+in+Developing+Topics+Poster+Presentation+at+AAIC+2026/26702376.html Mon, 29 Jun 2026 08:01:00 -0400 A.06822034 O.17919569 O.20026344 VYGR http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Voyager+Therapeutics%2C+++++For%3A+Jun+09++Filed+by%3A+MACKEY+CATHERINE+J/26635623.html si-local-file:///var/storage/secattach/20260611/26635623.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Voyager+Therapeutics%2C+++++For%3A+Jun+09++Filed+by%3A+MACKEY+CATHERINE+J/26635623.html Thu, 11 Jun 2026 16:06:00 -0400 O.17919569 VYGR http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Voyager+Therapeutics%2C+++++For%3A+Jun+09++Filed+by%3A+MACKEY+CATHERINE+J/26635623.html si-local-file:///var/storage/secattach/20260611/26635623.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Voyager+Therapeutics%2C+++++For%3A+Jun+09++Filed+by%3A+MACKEY+CATHERINE+J/26635623.html Thu, 11 Jun 2026 16:06:00 -0400 O.17919569 VYGR http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Voyager+Therapeutics%2C+++++For%3A+Jun+09++Filed+by%3A+SCANGOS+GEORGE+A/26635644.html si-local-file:///var/storage/secattach/20260611/26635644.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Voyager+Therapeutics%2C+++++For%3A+Jun+09++Filed+by%3A+SCANGOS+GEORGE+A/26635644.html Thu, 11 Jun 2026 16:06:00 -0400 O.17919569 VYGR http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Voyager+Therapeutics%2C+++++For%3A+Jun+09++Filed+by%3A+SCANGOS+GEORGE+A/26635644.html si-local-file:///var/storage/secattach/20260611/26635644.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Voyager+Therapeutics%2C+++++For%3A+Jun+09++Filed+by%3A+SCANGOS+GEORGE+A/26635644.html Thu, 11 Jun 2026 16:06:00 -0400 O.17919569 VYGR